New Screening Tool Promotes Multidisciplinary Approach to Type 2 Inflammation-Related Diseases
Type 2 (T2) inflammation underlies a range of diseases that often coexist, including asthma, atopic dermatitis, eosinophilic esophagitis, and allergic rhinitis. Despite advancements in understanding and treating these conditions, the absence of effective interdisciplinary communication and diagnostic tools frequently delays proper care.
A group of specialists spanning pneumology, dermatology, immunology, allergology, and otorhinolaryngology collaborated to develop a novel screening questionnaire tailored for all levels of healthcare. The tool focuses on identifying the hallmark symptoms of T2 inflammation-related diseases, such as wheezing in asthma, nasal obstruction in chronic rhinosinusitis, and food impaction in eosinophilic esophagitis.
The questionnaire, crafted in patient-friendly language, aims to help primary care physicians and specialists recognize potential coexisting T2 diseases and refer patients to the appropriate experts promptly. Its design emphasizes simplicity and adaptability, enabling effective use during routine consultations.
Key Features of the Screening Tool
- Simplified Patient Language: Questions are written in plain language, mirroring how patients describe symptoms like wheezing, nasal congestion, or skin rashes.
- Multispecialty Utility: Designed for use at all levels of care, the questionnaire facilitates timely referrals to appropriate specialists.
- Rapid Administration: Quick enough to fit into the time constraints of typical consultations, making it practical for primary care and specialist settings alike.
A Game-Changer in Multidisciplinary Care
Type 2 inflammation often manifests in overlapping diseases, yet lack of interdisciplinary coordination can lead to delays in treatment. For example:
- A patient with asthma might also have atopic dermatitis and allergic rhinitis, conditions frequently missed by siloed care approaches.
- Early detection and management can prevent complications like recurrent infections, chronic discomfort, or diminished quality of life.
The developers are undertaking rigorous validation of the tool, including feedback from patients and multidisciplinary physicians. Future studies will examine the tool’s impact on early diagnosis, referral efficiency, and overall quality of care.
By providing a unified approach to diagnosing and managing T2 inflammation, this screening tool addresses a critical gap in healthcare, promising improved outcomes for patients with overlapping inflammatory diseases.
Reference
Palomares O, Cisneros C, Ortiz de Frutos FJ, Villacampa JM, Dávila I. Multidisciplinary management of type 2 inflammation diseases using a screening tool. Front Allergy. 2024;5:1427279. Published 2024 Jul 18. doi:10.3389/falgy.2024.1427279
© 2025 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of The Dermatologist or HMP Global, their employees, and affiliates.
The APP Institute is dedicated to educating and informing advanced practice providers on clinical topics and practical issues to support the profession and improve the quality of patient care across the spectrum of dermatology.
The APP Institute | Dermatology is designed for Advanced Practice Providers who specialize in Dermatology, to further their education and increase their knowledge to achieve better patient outcomes. Explore cutting-edge research, innovative treatment options, and new therapeutic methods, while remaining focused on the fundamental principles and terminology associated with Dermatology. Engage year-round with the Dermatology Learning Network to access clinical insights, interactive features, research news updates, accredited continuing education programs, and more.
